Portfolio company
Eyestem
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
2 investors
Sectors
About
The company develops cell replacement therapies to treat incurable blindness and retinal diseases for patients globally.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
StemSight
This company develops stem cell therapies using biomaterials to treat corneal blindness in patients with limbal stem cell deficiency and other eye conditions.
InGel Therapeutics
The company develops stem-cell therapies and biodegradable hydrogels for patients suffering from retinal degeneration and blinding diseases like retinitis pigmentosa.
Ray Therapeutics
The company develops optogenetic gene therapies to restore vision for patients with blinding retinal diseases.
Eyexora
This company develops therapeutics and medical devices for ophthalmic diseases to treat patients with vision-threatening conditions.
RhyGaze
This biotechnology company develops optogenetic gene therapies to restore vision for patients with retinal diseases causing blindness.
CIRC Biosciences
This cell therapy company develops chemically induced retinal cells to restore vision for patients with macular degeneration and retinitis pigmentosa.
Beacon Therapeutics
This company develops ophthalmic gene therapies to restore vision for patients with rare and prevalent retinal diseases causing blindness.
Cirrus Therapeutics
This company develops gene and cell therapies to treat age-related macular degeneration and chronic vision loss for patients with blinding eye diseases.